Exchange: NSE Sector: Healthcare Industry: Drug Manufacturers—General
-0.18% INR1 384.75
America/New_York / 8 mai 2024 @ 05:59
FUNDAMENTALS | |
---|---|
MarketCap: | 1 118 040 mill |
EPS: | 45.83 |
P/E: | 30.21 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 807.40 mill |
Avg Daily Volume: | 1.489 mill |
RATING 2024-05-08 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Buy | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | n/a | n/a | n/a | |||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 30.21 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE 30.21 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
INR1 817.28 (31.23%) INR432.53 |
Date: 2024-05-08 |
Expected Trading Range (DAY) |
---|
INR 1 353.93 - 1 417.87 ( +/- 2.31%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | INR1 384.75 (-0.18% ) |
Volume | 1.498 mill |
Avg. Vol. | 1.489 mill |
% of Avg. Vol | 100.58 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.